Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
Abstract:
Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate–dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the Unite...
Source: Journal of Cardiovascular Pharmacology - Category: Cardiology Tags: Perspectives Source Type: research
More News: ALS | Austria Health | Belgium Health | Calcium | Cardiogenic Shock | Cardiology | Cardiomyopathy | Cardiovascular | Cardiovascular & Thoracic Surgery | Croatia Health | Cyprus Health | Czechia Health | Drugs & Pharmacology | Emergency Medicine | Estonia Health | Finland Health | France Health | Germany Health | Greece Health | Heart | Heart Failure | Hungary Health | Hypertension | Italy Health | Netherlands Health | Norway Health | Poland Health | Portugal Health | Potassium | Pulmonary Hypertension | Russia Health | Slovenia Health | Spain Health | Sweden Health | Switzerland Health | UK Health | Ukraine Health | USA Health